Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Oral Docetaxel"'
Publikováno v:
Clinical Pharmacology: Advances and Applications, Vol Volume 13, Pp 21-32 (2021)
Marit Vermunt,1 Serena Marchetti,2 Jos Beijnen1,3,4 1Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066, CX, the Netherlands; 2Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066,
Externí odkaz:
https://doaj.org/article/091def07b27d48a1b852653d790f61e6
Autor:
Jeroen J. M. A. Hendrikx, Frederik E. Stuurman, Ji‐Ying Song, Vincent A. deWeger, Jurjen S. Lagas, Hilde Rosing, Jos H. Beijnen, Alfred H. Schinkel, Jan H. M. Schellens, Serena Marchetti
Publikováno v:
Pharmacology Research & Perspectives, Vol 8, Iss 4, Pp n/a-n/a (2020)
Abstract Oral administration of docetaxel in combination with the CYP3A4 inhibitor ritonavir is used in clinical trials to improve oral bioavailability of docetaxel. Diarrhea was the most commonly observed and dose‐limiting toxicity. This study com
Externí odkaz:
https://doaj.org/article/312864ef1c70464298e06dea8e715675
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Clinical Pharmacology : Advances and Applications
Marit Vermunt,1 Serena Marchetti,2 Jos Beijnen1,3,4 1Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066, CX, the Netherlands; 2Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57426e9cddc00639de19ac0d251a1b82
https://doi.org/10.2147/cpaa.s292746
https://doi.org/10.2147/cpaa.s292746
Publikováno v:
Pharmaceutical Research. 38:1419-1428
The current study aimed to develop a novel milk-based formulation of docetaxel, a sparingly soluble antineoplastic agent, administered so far exclusively by the intravenous route and evaluate its oral bioavailability. Pre-formulation studies included
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d0c4e9a3a6f28823374c201fb368f9c8
https://doi.org/10.1007/s11095-021-03085-x
https://doi.org/10.1007/s11095-021-03085-x
Autor:
Dick Pluim, Alwin D. R. Huitema, Thomas P. C. Dorlo, Maarten van Eijk, Jos H. Beijnen, Serena Marchetti
Publikováno v:
The Pharmacogenomics Journal. 21:336-345
The anticancer drug docetaxel exhibits large interpatient pharmacokinetic and pharmacodynamic variability. In this study, we aimed to assess the functional significance of 14 polymorphisms in the CYP3A, CYP1B1, ABCB1, ABCC2, and SLCO1B3 genes for the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e531b209eb43c0583e74d32dd4c8bfef
https://doi.org/10.1038/s41397-021-00213-z
https://doi.org/10.1038/s41397-021-00213-z
Autor:
Elizabeth Hernandez, Sophia Le, Tina Nguyen, Yuzhou Liu, Jer Tsong Hsieh, Payal Kapur, Chun Mien Chang, Yu-An Chen, Keith P. Johnston, Xiaowei Dong
Publikováno v:
Journal of Biomedical Nanotechnology. 16:583-593
Metronomic chemotherapy, giving low doses of chemotherapeutics (e.g., docetaxel) on a frequent schedule over a long time, may improve outcomes and reduce side effects for cancer patients. Oral medications are vital for applying metronomic chemotherap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1c893a322648e424c880a347ad366db
https://doi.org/10.1166/jbn.2020.2925
https://doi.org/10.1166/jbn.2020.2925
Autor:
Thomas P. C. Dorlo, Vincent A. de Weger, Alwin D. R. Huitema, Rik E Stuurman, Serena Marchetti, Jos H. Beijnen, Bastiaan Nuijen, Huixin Yu, Jan H.M. Schellens, Julie M Janssen
Publikováno v:
Investigational New Drugs. 38:1526-1532
Introduction Oral formulations of docetaxel have successfully been developed as an alternative for intravenous administration. Co-administration with the enzyme inhibitor ritonavir boosts the docetaxel plasma exposure. In dose-escalation trials, the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4caa582dd9334325ff2ab9ed6a12bfd3
https://doi.org/10.1007/s10637-020-00935-0
https://doi.org/10.1007/s10637-020-00935-0
Autor:
Hendrikx, Jeroen J M A, Stuurman, Frederik E, Song, Ji-Ying, de Weger, Vincent A, Lagas, Jurjen S, Rosing, Hilde, Beijnen, Jos H, Schinkel, Alfred H, Schellens, Jan H M, Marchetti, Serena, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Pharmacology Research & Perspectives, Vol 8, Iss 4, Pp n/a-n/a (2020)
Pharmacology Research & Perspectives
Pharmacology research & perspectives, 8(4). Wiley-Blackwell Publishing Ltd
Pharmacology Research & Perspectives
Pharmacology research & perspectives, 8(4). Wiley-Blackwell Publishing Ltd
Oral administration of docetaxel in combination with the CYP3A4 inhibitor ritonavir is used in clinical trials to improve oral bioavailability of docetaxel. Diarrhea was the most commonly observed and dose‐limiting toxicity. This study combined pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9db09f9e8a604f657ca7ca0b5c8dd324
https://doaj.org/article/312864ef1c70464298e06dea8e715675
https://doaj.org/article/312864ef1c70464298e06dea8e715675